Quentin M. Anstee

7 ta ish

NIHR Newcastle Biomedical Research Centre

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

   Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu +50

   Sharh maqolaOAOchiq kirish20235 iqtibos

   ABIABI:AkademIndex/2026.other.008454

2. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

   Zobair M. Younossi, Quentin M. Anstee, M. Marietti +5

   Sharh maqolaOAOchiq kirish20174 iqtibos

   ABIABI:AkademIndex/2026.other.003684

3. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies

   Ahmad Al‐Serri, Quentin M. Anstee, Luca Valenti +8

   Maqola20113 iqtibos

   ABIABI:AkademIndex/2026.other.723584

4. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

   Mohammed Eslam, Philip N. Newsome, Shiv Kumar Sarin +29

   Sharh maqolaOAOchiq kirish20202 iqtibos

   ABIABI:AkademIndex/2026.other.003730

5. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis

   Yasaman Vali, Jenny Lee, Jérôme Boursier +25

   Sharh maqolaOAOchiq kirish20202 iqtibos

   ABIABI:AkademIndex/2026.other.003731

6. Advancing the global public health agenda for NAFLD: a consensus statement

   Jeffrey V. Lazarus, Henry E. Mark, Quentin M. Anstee +97

   Sharh maqolaOAOchiq kirishLiver Disease Diagnosis and TreatmentNature Reviews Gastroenterology & Hepatology20211 iqtibos

   ABIABI:AkademIndex/2021.review-article.000002

7. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

   Jeffrey V. Lazarus, Henry E. Mark, M Villota-Rivas +97

   MaqolaOAOchiq kirish20210 iqtibos

   ABIABI:AkademIndex/2021.article.014111